Reimbursement win for Ascentage in China

A new indication for olverembatinib, developed by Suzhou-based Ascentage Pharma (HKEX: 6855) will be added to China’s National Reimbursement Drug List (NRDL) from next year.

The firm said the inclusion, which was achieved through a “simple contract renewal process,” would expand the drug’s coverage to certain adults with chronic myeloid leukemia (CML), who are resistant or intolerant to tyrosine kinase inhibitors.

Olverembatinib, the first third-generation BCR-ABL inhibitor approved by China’s National Medical Products Administration, is jointly commercialized by Ascentage Pharma and Innovent Biologics (HKG: 1801).